Aziz Nazha1,2, Mrinal M Patnaik3. 1. Leukemia Program, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA. nazhaa@ccf.org. 2. Lerner College of Medicine, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Desk R35 9500 Euclid Ave, Cleveland, OH, 44195, USA. nazhaa@ccf.org. 3. Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Abstract
PURPOSE OF REVIEW: To evaluate established prognostic models in chronic myelomonocytic leukemia (CMML) and describe the challenges associated with their application in clinical practice. RECENT FINDINGS: CMML is a clonal hematopoietic stem cell disorder with heterogeneous clinical and molecular features. Outcomes of CMML patients can vary from indolent disease with expected survival measured in years versus proliferative subtypes with rapid progression to acute myeloid leukemia and survival measured in months. Several prognostic scoring systems have been developed to risk stratify CMML patients. While all these models are valid, they demonstrate significant predictive heterogeneity. Significant intra-patient (applying different models in the same patient giving rise to different prognostic results) and intra-model (patients in a similar prognostic group by a given model can be reclassified to different risk groups by other models) heterogeneities exist when applying current CMML prognostic models in the clinic. A personalized prediction approach may open new opportunities in risk stratifying patients with CMML and other myeloid malignancies.
PURPOSE OF REVIEW: To evaluate established prognostic models in chronic myelomonocytic leukemia (CMML) and describe the challenges associated with their application in clinical practice. RECENT FINDINGS:CMML is a clonal hematopoietic stem cell disorder with heterogeneous clinical and molecular features. Outcomes of CMMLpatients can vary from indolent disease with expected survival measured in years versus proliferative subtypes with rapid progression to acute myeloid leukemia and survival measured in months. Several prognostic scoring systems have been developed to risk stratify CMMLpatients. While all these models are valid, they demonstrate significant predictive heterogeneity. Significant intra-patient (applying different models in the same patient giving rise to different prognostic results) and intra-model (patients in a similar prognostic group by a given model can be reclassified to different risk groups by other models) heterogeneities exist when applying current CMML prognostic models in the clinic. A personalized prediction approach may open new opportunities in risk stratifying patients with CMML and other myeloid malignancies.
Authors: Mrinal M Patnaik; Emnet A Wassie; Terra L Lasho; Curtis A Hanson; Rhett Ketterling; Ayalew Tefferi Journal: Am J Hematol Date: 2015-04-01 Impact factor: 10.047
Authors: Francesco Onida; Hagop M Kantarjian; Terry L Smith; Greg Ball; Michael J Keating; Elihu H Estey; Armand B Glassman; Maher Albitar; Monica I Kwari; Miloslav Beran Journal: Blood Date: 2002-02-01 Impact factor: 22.113
Authors: Aziz Nazha; David P Seastone; Michael Keng; Sean Hobson; Matt Kalaycio; Jaroslaw P Maciejewski; Mikkael A Sekeres Journal: Leuk Lymphoma Date: 2015-09-22
Authors: M M Patnaik; E Padron; R R LaBorde; T L Lasho; C M Finke; C A Hanson; J M Hodnefield; R A Knudson; R P Ketterling; A Al-kali; A Pardanani; N A Ali; R S Komrokji; R S Komroji; A Tefferi Journal: Leukemia Date: 2013-03-27 Impact factor: 11.528
Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman Journal: Blood Date: 2016-04-11 Impact factor: 22.113
Authors: Yanbo Nie; Liang Shao; Hong Zhang; Colin K He; Hongyu Li; Junyan Zou; Long Chen; Huaiyue Ji; Hao Tan; Yani Lin; Kun Ru Journal: Exp Hematol Oncol Date: 2022-05-24
Authors: Peter Valent; Attilio Orazi; Michael R Savona; Mrinal M Patnaik; Francesco Onida; Arjan A van de Loosdrecht; Detlef Haase; Torsten Haferlach; Chiara Elena; Lisa Pleyer; Wolfgang Kern; Tea Pemovska; Gregory I Vladimer; Julie Schanz; Alexandra Keller; Michael Lübbert; Thomas Lion; Karl Sotlar; Andreas Reiter; Theo De Witte; Michael Pfeilstöcker; Klaus Geissler; Eric Padron; Michael Deininger; Alberto Orfao; Hans-Peter Horny; Peter L Greenberg; Daniel A Arber; Luca Malcovati; John M Bennett Journal: Haematologica Date: 2019-05-02 Impact factor: 9.941